246
Views
17
CrossRef citations to date
0
Altmetric
Research Article

Comparison of cefpodoxime proxetil release and antimicrobial activity from tablet formulations: Complexation with hydroxypropyl-β-cyclodextrin in the presence of water soluble polymer

, &
Pages 689-696 | Received 05 May 2011, Accepted 05 Sep 2011, Published online: 19 Oct 2011

References

  • Karthikeyan D, Karthikeyan M, Karthikeyan D, Karthikeyan M. 2010. Development of a new single dose extended release formulation of cefpodoxime proxetil. Asian Pas J of Tropical Medicine, 117–120.
  • Sader HS, Jones RN, Washington JA, Murray PR, Gerlach EH, Allen SD et al. 1993. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers. Diagn Microbiol Infect Dis, 17:143–150.
  • Nicolaos G, Crauste-Manciet S, Farinotti R, Brossard D. (2003). Improvement of cefpodoxime proxetil oral absorption in rats by an oil-in-water submicron emulsion. Int J Pharm, 263:165–171.
  • Borin MT. (1991). A review of the pharmacokinetics of cefpodoxime proxetil. Drugs, 42 Suppl 3:13–21.
  • Kakumanu VK, Arora VK, Bansal AK. (2008). Gastro-retentive dosage form for improving bioavailability of Cefpodoxime proxetil in rats. Yakugaku Zasshi, 128:439–445.
  • Date AA, Nagarsenker MS. (2007). Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. Int J Pharm, 329:166–172.
  • Finsher JH. (1968). Particle size of drugs and its relationship to absorption and activity. J Pharm Sci, 57:1825–1835.
  • Salústio PJ, Cabral-Marques HM, Costa PC, Pinto JF. (2011). Comparison of ibuprofen release from minitablets and capsules containing ibuprofen: ß-cyclodextrin complex. Eur J Pharm Biopharm, 78:58–66.
  • Ng WK, Kwek JW, Yuen A, Tan CL, Tan R. 2010. Effect of milling on DSC thermogram of excipient adipic acid. AAPS PharmSciTech, 11:159–167.
  • Talari R, Varshosaz J, Mostafavi SA, Nokhodchi A. 2010. Gliclazide microcrystals prepared by two methods of in situ micronization: pharmacokinetic studies in diabetic and normal rats. AAPS PharmSciTech, 11:786–792.
  • Engers D, Teng J, Jimenez-Novoa J, Gent P, Hossack S, Campbell C et al. 2010. A solid-state approach to enable early development compounds: selection and animal bioavailability studies of an itraconazole amorphous solid dispersion. J Pharm Sci, 99:3901–3922.
  • Rupp C, Steckel H, Müller BW. 2010. Solubilization of poorly water-soluble drugs by mixed micelles based on hydrogenated phosphatidylcholine. Int J Pharm, 395:272–280.
  • Brewster ME, Loftsson T. (2007). Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev, 59:645–666.
  • Yamamura S, Rogers JA. (1996). Characterization and dissolution behavior of nifedipine and phosphatidylcholine binary systems. Int J Pharm 130:65–73.
  • Reddy JRK, Chetty CM. 2010. Enhancement of solubility of nateglinide by solid dispersion technique. J Pharm Pharmacol 62:1330–1331.
  • Dhareshwar SS, Stella VJ. 2010. A novel prodrug strategy for beta-dicarbonyl carbon acids: syntheses and evaluation of the physicochemical characteristics of C-phosphoryloxymethyl (POM) and phosphoryloxymethyloxymethyl (POMOM) prodrug derivatives. J Pharm Sci, 99:2711–2723.
  • Yavuz B, Bilensoy E, Vural I, Sumnu M. 2010. Alternative oral exemestane formulation: improved dissolution and permeation. Int J Pharm, 398:137–145.
  • Albers E, Müller BW. (1995). Cyclodextrin derivatives in pharmaceutics. Crit Rev Ther Drug Carrier Syst, 12:311–337.
  • Wen Kou, Cuifang Cai, Shuying Xu, Huan Wang, Jing Liu, Dan Yang, Tianhong Zhang. (2011). In vitro and in vivo evaluation of novel immediate release carbamazepine tablets: Complexation with hydroxypropyl–cyclodextrin in the presence of HPMC. Int J of Pharmaceutics, 409:75–80.
  • Irie T, Uekama K. (1997). Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci, 86:147–162.
  • Gould S, Scott RC. (2005). 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol, 43:1451–1459.
  • Faucci MT, Mura P. (2001). Effect of water-soluble polymers on naproxen complexation with natural and chemically-modified- β-cyclodextrins. Drug Dev Ind Pharm 27:311–319.
  • Smith JS, Macrae RJ, Snowden MJ. (2005). Effect of SBE7-beta-cyclodextrin complexation on carbamazepine release from sustained release beads. Eur J Pharm Biopharm, 60:73–80.
  • Cirri M, Righi MF, Maestrelli F, Mura P, Valleri M. (2009). Development of glyburide fast-dissolving tablets based on the combined use of cyclodextrins and polymers. Drug Dev Ind Pharm, 35:73–82.
  • Barbucci R, Magnani A, Consumi M. (2000). Swelling behavior of carboxymethylcellulose hydrogels in relation to cross-linking, pH, and charge density. Macromolecules, 33:7475–7480.
  • Benmouhoub N, Simmonet N, Agoudjil N, Coradin T. (2008). Aqueous sol–gel routes to bio-composite capsules and gels. Green Chemistry, 10:957–964.
  • Kulkarni RV, Sa B. (2008). Evaluation of pH-sensitivity and drug release characteristics of (polyacrylamide-grafted-xanthan)-carboxymethyl cellulose-based pH-sensitive interpenetrating network hydrogel beads. Drug Dev Ind Pharm, 34:1406–1414.
  • Jiang LY, Li YB, Wang XJ, Zhang L, Wen JQ, Gong M. (2008). Preparation and properties of nano-hydroxyapatite/chitosan/carboxymethyl cellulose composite scaffold. Carbohydrate Polymers, 74:680–684.
  • Pasqui D, Rossi A, Di Cintio F, Barbucci R. (2007). Functionalized titanium oxide surfaces with phosphated carboxymethyl cellulose: Characterization and bonelike cell behavior. Biomacromolecules, 8:3965–3972.
  • Higuchi T, Connors KA. (1965). Phase-solubility techniques. Adv Anal Chem Instrum 4:117–212.
  • Davis ME, Brewster ME. (2004). Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov, 3:1023–1035.
  • Katzhendler I, Azoury R, Friedman M. (1998). Crystalline properties of carbamazepine in sustained release hydrophilic matrix tablets based on hydroxypropyl methylcellulose. J Control Release, 54:69–85.
  • Kakumanu VK, Arora V, Bansal AK. (2006). Investigation of factors responsible for low oral bioavailability of cefpodoxime proxetil. Int J Pharm, 317:155–160.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.